Literature DB >> 19188098

Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection.

Jean L J M Scheijen1, Marjo P H van de Waarenburg, Coen D A Stehouwer, Casper G Schalkwijk.   

Abstract

A rapid and sensitive single-column high-performance liquid chromatography method and application for the detection of protein bound pentosidine is described. Pentosidine, a cross-link between arginine and lysine, is a well-characterized advanced glycation endproduct. In order to detect protein-bound pentosidine, plasma proteins were hydrolysed in 6N HCl. Detection of pentosidine is done based on its own fluorescence characteristics using fluorimetric detection (E(x)=325 nm, E(m)=385 nm). Separation is done, with a run-to-run time of 30 min, on a C(18) Allspehere ODS-II column with a citric acid acetonitrile buffer. This detection enables sensitive and specific determination of protein bound pentosidine in plasma with a detection limit of 2.2 nmol/l or 0.02 pmol/mg protein (signal-to-noise: 6). The intra-assay coefficient variation is 6.5% at a plasma pentosidine concentration of 0.47 pmol/mg protein and 2.0% at a concentration of 1.27 pmol/mg protein. The inter-assay coefficient variation is 3.1% at a plasma pentosidine concentration of 0.43 pmol/mg protein and 1.6% at a concentration of 1.40 pmol/mg protein. Linearity is tested in 4 different plasma samples and showed linearity (0-200 nmol/l, r(2)>0.99). Recovery of pentosidine in 4 different plasma samples at different concentration levels is 102+/-10% (mean+/-SD). Using this method protein bound pentosidine concentration is investigated in healthy controls (n=24, age 67+/-9 years) and patients with end stage renal disease (n=24, age 65+/-10 years). Higher plasma concentrations of protein bound pentosidine are measured in the patient group as compared with the control group 3.05 (2.03-3.92)pmol/mg protein and 0.21 (0.19-0.33)pmol/mg protein, respectively (median (interquartile range), p<0.00001). These results are consistent with previously reported results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188098     DOI: 10.1016/j.jchromb.2009.01.022

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  19 in total

Review 1.  Oxidation as an important factor of protein damage: Implications for Maillard reaction.

Authors:  L Trnkova; J Drsata; I Bousova
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

2.  Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats.

Authors:  Olaf Brouwers; Petra M Niessen; Isabel Ferreira; Toshio Miyata; Peter G Scheffer; Tom Teerlink; Patrick Schrauwen; Michael Brownlee; Coen D Stehouwer; Casper G Schalkwijk
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

3.  Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress.

Authors:  O Brouwers; P M Niessen; G Haenen; T Miyata; M Brownlee; C D Stehouwer; J G De Mey; C G Schalkwijk
Journal:  Diabetologia       Date:  2010-02-26       Impact factor: 10.122

Review 4.  Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.

Authors:  Suzan Willemsen; Jasper W L Hartog; M Rebecca Heiner-Fokkema; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.

Authors:  Johanna W Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D Stehouwer
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

6.  N-acetylcysteine reduces oxidative stress in sickle cell patients.

Authors:  Erfan Nur; Dees P Brandjes; Tom Teerlink; Hans-Martin Otten; Ronald P J Oude Elferink; Frits Muskiet; Ludo M Evers; Hugo ten Cate; Bart J Biemond; Ashley J Duits; John-John B Schnog
Journal:  Ann Hematol       Date:  2012-02-10       Impact factor: 3.673

Review 7.  The impact of advanced glycation end products on bone properties in chronic kidney disease.

Authors:  John G Damrath; Amy Creecy; Joseph M Wallace; Sharon M Moe
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-07-01       Impact factor: 3.416

8.  Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.

Authors:  Katherine L O'Grady; Sundeep Khosla; Joshua N Farr; Olga P Bondar; Elizabeth J Atkinson; Sara J Achenbach; Brittany A Eckhardt; Brianne S Thicke; Amanda J Tweed; Tammie L Volkman; Matthew T Drake; Jolaine M Hines; Ravinder J Singh
Journal:  J Appl Lab Med       Date:  2020-05-01

9.  Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD.

Authors:  Poornima Gopal; Niki L Reynaert; Jean L J M Scheijen; Casper G Schalkwijk; Frits M E Franssen; Emiel F M Wouters; Erica P A Rutten
Journal:  Respir Res       Date:  2014-02-25

10.  Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.

Authors:  Alaa Alkhalaf; Nanne Kleefstra; Klaas H Groenier; Henk J G Bilo; Reinold O B Gans; Peter Heeringa; Jean L Scheijen; Casper G Schalkwijk; Gerjan J Navis; Stephan J L Bakker
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.